Skip to main content
Caplight Logo









Mirxes

Mirxes

Public
SingaporeBiotechhttps://www.mirxes.com

Mirxes is now publicly traded

The data on this page reflects Mirxes's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

May 23, 2025

Last Round

Debt

Jan 13, 2025

Total Funding Raised

$322.75M

Company Overview

MiRXES is a healthcare company that develops a diagnostic test platform for the early detection of cancer through microRNA quantification, enabling healthcare professionals to identify the disease at asymptomatic stages.

Sector

Biotech

AI Layer

Application

Keywords

gastric cancer screening blood testblood-based microRNA (miRNA) diagnostic testliquid biopsy for cancer screeningprecision multi-omics services for biopharmamulti-cancer early detection testlung cancer screening blood testAI-driven molecular diagnosticsin-vitro diagnostic (IVD) test kitmiRNA biomarker detection platformclinical sequencing serviceRT-PCR diagnostic test

Mirxes Comparables

Compare Mirxes with similar companies based on industry and business-model similarity.

Mirxes comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Craif Inc.
72%
Pharus Diagnostics
71%
4D Lifetec
71%

Mirxes Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOMay 23, 2025
DebtJan 13, 2025
Series DJul 25, 2023
Series CJul 8, 2021
Series ANov 27, 2018
Seed
Sep 5, 2016

Mirxes Investors

Notable investors and investment history

Mirxes Filings

Explore SEC and related filing metadata, where available.

Mirxes filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersSingapore
Employee Range156
Year Founded2014
Last FundingJan 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?